- Xaira X Design Generated a Cancer Antibody Lead in Seven Weeks · Biotech
Xaira Therapeutics disclosed its X Design model produced progressable antibody leads for two pipeline targets, including a de novo cancer candidate built in seven weeks and a difficult GPCR program.
- Hansa Biopharma Deploys Cradle AI Across Autoimmune Discovery Pipeline · Biotech
Hansa Biopharma will use Cradle's end to end protein engineering platform across autoimmune programs, joining a wave of October 2026 deals that move AI design from pilots into named pipeline stages.
- Profluent Will Design Enzyme Therapies With BioMarin Using AI Models · Biotech
Profluent and BioMarin announced on 30 September 2026 a collaboration to generate and optimize enzyme replacement candidates using Profluent protein language models.
- Microsoft Quine Prioritized Tumor State Shifts and Validated Them in Wet Lab · Biotech
Microsoft Research unveiled Quine on 29 September 2026, a multimodal biology harness that ranked compounds for tumor state transitions and validated top picks with Broad Institute collaborators over a weekend.
- Roche Pays Atavistik $70 Million Upfront for Allosteric CVRM Discovery · Biotech
Atavistik Bio will use its AMPS metabolite protein screening platform to discover allosteric small molecules for cardiovascular, renal, and metabolic targets under a Roche collaboration worth up to $1.9 billion in milestones.
- Novo Nordisk Will Test Claude Science Inside Drug Discovery Workflows · Biotech
Novo Nordisk and Anthropic announced on 16 September 2026 a collaboration to apply Claude Science and frontier models to biological reasoning tasks in R&D plus AI driven software development.
- AbbVie Partners With Iambic on AI Small Molecule Discovery · Biotech
AbbVie and Iambic announced a multi year collaboration on 21 September 2026 to apply Iambic's Enchant v3 AI platform across immunology, neuroscience, and oncology small molecule programs.
- Earendil Labs Signs Genentech Bispecific Deal Worth Up to $1.5 Billion · Biotech
Earendil Labs announced a Genentech collaboration on 24 September 2026 to discover bispecific cancer antibodies using generative protein engineering, extending AI biologics deal flow after major enzyme discovery headlines.
- Anthropic ART Enzyme Find Shows AI Can Flag Biology Leads Not Yet Tools · Biotech
Anthropic reports Claude agents found the ART enzyme system after searching 1.9 billion protein clusters, but the preprint says reverse transcriptase activity remains unproven.
- Four Pharma Giants Begin Federated Training on Binding Affinity Models · Biotech
AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson will jointly train AISB Bind through Apheris without sharing raw compound libraries.
- AbbVie Bets Enchant v3 Multimodal AI Across Three Therapeutic Areas · Biotech
AbbVie and Iambic announced a multi year deal on 21 September to apply the Enchant v3 transformer, trained on more than 6,000 molecular properties, across immunology, neuroscience, and oncology discovery.
- Mithrl Opens Mithrl 1 Early Access With Biomedical World Model Inside Customer Environments · Biotech
Mithrl launches Mithrl 1 early access on 21 September 2026, pairing a validated biomedical world model with agentic routing inside each biopharma team's own environment.
- Inductive Beacon 2 Makes Human Dose Computable From Structure Alone · Biotech
Inductive launched Beacon 2 on 17 September to predict efficacious human dose from chemical structure, reporting a 17 fold improvement in an agentic optimization loop.
- FDA Clears Fayuvi as First Therapy for Pediatric Sanfilippo Syndrome A · Biotech
Ultragenyx won FDA approval for Fayuvi on 17 September 2026, the first labeled therapy for Sanfilippo syndrome type A in children with preserved neurodevelopmental function, following a prior complete response letter on manufacturing.
- Insilico Publishes LongevityBench and Compact Longevity LLMs in Cell · Biotech
Insilico Medicine published LongevityBench in Cell on 17 September 2026, releasing 17 aging biology tasks, five compact Longevity LLMs, and an open Longevity Claw research interface.
- Novo Nordisk Tests Claude in Drug Discovery Workflows · Biotech
Novo Nordisk partnered with Anthropic on 16 September 2026 to deploy Claude and Claude Science inside research and development workflows, signaling that large pharma will treat frontier models as reasoning infrastructure rather than a standalone discovery engine.
- Sponsor RTCT Comments Show AI Enters Trials Through Data Plumbing First · Biotech
Industry comment letters on FDA real time clinical trials show sponsors want AI in reconciliation and surveillance first, with human review gates on dose and safety decisions.
- FDA Clears Pixclara as First Amino Acid PET Agent for Glioma Imaging · Biotech
Telix Pharmaceuticals said on 14 September 2026 the FDA approved Pixclara, floretyrosine F 18, as the first amino acid PET imaging drug for glioma, helping distinguish recurrence from treatment related change.
- FDA Expands Sevabertinib to First Line HER2 Mutated Lung Cancer · Biotech
On 9 September 2026 the FDA granted accelerated approval to sevabertinib for first line treatment of locally advanced or metastatic HER2 mutated non squamous NSCLC.
- Pharming Wins First APDS Label for Children Aged Four Through Eleven · Biotech
The FDA approved expanded Joenja dosing on 11 September 2026 for children aged four to eleven with APDS who weigh at least 27 kg, making leniolisib the first approved treatment for that pediatric cohort in the United States.
- Scholar Rock Wins FDA Approval for Spinal Muscular Atrophy Therapy · Biotech
The FDA approved Scholar Rock's therapy for a rare genetic muscle weakness condition on 11 September, giving the company its first commercial product in a neuromuscular market with few options.
- PostEra Sells AI Designed Fertility Programs to EMD Serono in a Platform Exit Test · Biotech
EMD Serono acquired PostEra's FSHR and LHCGR agonist programs, oral small molecule fertility candidates designed with PostEra's Proton AI platform and still in preclinical development.
- Recursion Clears IND for AI Designed PI3Kα Inhibitor REC 7735 · Biotech
Recursion said the FDA cleared REC 7735, an AI designed PI3Kα H1047R inhibitor, and plans to start the Phase 1/2 ZINNIA trial in the second half of 2026 after a 10 month, 242 compound design cycle.
- FDA Clears Etcamah as First Line Oral SERD for ESR1 Mutated Breast Cancer · Biotech
FDA accelerated approval of AstraZeneca's oral SERD Etcamah pairs first line ESR1 mutated breast cancer treatment with Guardant360 CDx liquid biopsy testing.
- Ionis Wins FDA Approval for First Alexander Disease Therapy Zanvastro · Biotech
FDA approved Ionis Zanvastro as the first targeted therapy for Alexander disease, giving the biotech its first independent neurology launch.
- AbbVie Etentamig Hits 74 Percent ORR in Phase 3 CERVINO Myeloma Trial · Biotech
AbbVie reported on 3 September 2026 that Phase 3 CERVINO met ORR and PFS endpoints for etentamig in triple class exposed myeloma, with 74.0 percent ORR versus 45.7 percent and PFS hazard ratio 0.40. Full results arrive at IMS Glasgow on 25 September.
- BigHat Doses First Patient With an AI Designed CDH17 ADC in Phase 1 · Biotech
BigHat Biosciences dosed the first patient on 1 September 2026 in a Phase 1 study of BHB810, an AI designed CDH17 directed ADC for gastrointestinal cancers. Oncology R&D teams should watch whether developability choices from the platform survive early human safety and pharmacokinetic readouts.
- Ono Pharmaceutical Bets on Causal AI Digital Twins for Neurology Targets · Biotech
Ono Pharmaceutical partnered with Aitia to use causal AI digital twins for neurology target discovery, granting Ono an exclusive worldwide option on identified candidates. R&D leaders should watch whether option exercises follow within a year.
- Owkin Licenses K Pro and Multimodal Patient Data to Boehringer Ingelheim · Biotech
Owkin licensed its K Pro AI scientist and fresh multimodal oncology and immunology data to Boehringer Ingelheim, expanding a 2025 spatial biology pilot into a platform scale discovery partnership.
- DnaK and GATC Health Use AI to Rank 16 Oncology Candidates Early · Biotech
DnaK Therapeutics will use GATC Health's predictive AI to rank 16 oncology candidates before preclinical spend, with initial prioritization results expected this fall.
- Proteina and Twist Pair AI Antibody Design With High Volume Wet Lab Proof · Biotech
Proteina and Twist Bioscience agreed on 27 August 2026 to pair AI designed antibody libraries with large scale synthesis and wet lab validation, targeting a defined collaboration model by year end.
- Noetik Hits First GSK Milestone After Deploying OCTO VC Cancer Models · Biotech
Noetik hit the first GSK milestone after deploying OCTO VC cancer foundation models for virtual cell work and patient stratification under a 50 million dollar upfront licensing deal.
- Ainnocence Reports AINN P1 Lifts Antibody Affinity Ranking by 28 Percent · Biotech
Ainnocence reports its frozen AINN P1 encoder lifted antibody antigen affinity ranking correlation by about 28 percent over a from scratch baseline in cross validation. Teams should wait for prospective lab validation before changing lead rules.
- AutoBinder Agent Unifies Protein Binder Design Through MCP Tool Orchestration · Biotech
AutoBinder Agent uses MCP to orchestrate MaSIF, Rosetta, ProteinMPNN, and AlphaFold3 into one reproducible protein binder design workflow.
- Insilico Moves Rentosertib Into Phase III as First Fully AI Originated Drug at That Stage · Biotech
The Chinese biotech says its TNIK inhibitor for idiopathic pulmonary fibrosis cleared Phase IIa with a forced vital capacity signal strong enough to start a 320 patient pivotal program.
- Genentech Validates First AI Surfaced Neuroscience Target From Recursion Deal · Biotech
Genentech exercised a validated target option on a previously unexplored neuroscience target discovered through Recursion Pharmaceuticals phenomics platform, advancing it into small molecule early discovery.
- Claude Designed Working Protein Binders on 14 of 15 Lab Targets · Biotech
Anthropic said Claude designed binders for 14 of 15 protein targets with 22 to 35 percent hit rates, validated by Adaptyv Bio and Twist Bioscience, plus fast NMR and LC MS analysis.
- Chai Discovery Partners With BMS to Generate Antibodies From Scratch · Biotech
Chai Discovery partnered with Bristol Myers Squibb to apply its generative AI antibody design platform across BMS's portfolio, adding a fifth major pharma deal for the startup after its $400 million Series C.
- 175 AI Drug Programs Have Entered Trials but Zero FDA Approvals So Far · Biotech
Roughly 175 AI originated drug programs have entered human trials but zero hold full FDA approval as of August 2026, putting the verification era ahead of the hype cycle.
- Benchling Report Maps Biotech Shift Into the AI Builder Phase · Biotech
Benchling's 2026 survey of about 100 R&D organizations finds biotech entering a builder phase led by internal upskilling, embedded AI leadership, and integrated data infrastructure.